

Yusuf Menda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1221468/publications.pdf>

Version: 2024-02-01

90
papers

4,139
citations

147801

31
h-index

118850

62
g-index

92
all docs

92
docs citations

92
times ranked

4229
citing authors

#	ARTICLE	IF	CITATIONS
1	Response Assessment of Aggressive Non-Hodgkinâ€™s Lymphoma by Integrated International Workshop Criteria and Fluorine-18â€™ Fluorodeoxyglucose Positron Emission Tomography. Journal of Clinical Oncology, 2005, 23, 4652-4661.	1.6	364
2	⁹⁰ Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide. Journal of Clinical Oncology, 2010, 28, 1652-1659.	1.6	299
3	The Surgical Management of Small Bowel Neuroendocrine Tumors. Pancreas, 2017, 46, 715-731.	1.1	262
4	The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas, 2020, 49, 1-33.	1.1	226
5	The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. International Journal of Radiation Oncology Biology Physics, 2005, 63, 991-999.	0.8	189
6	A 36-Year Retrospective Analysis of the Efficacy and Safety of Radioactive Iodine in Treating Young Gravesâ€™ Patients. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4229-4233.	3.6	187
7	An Official American Thoracic Society/Society of Thoracic Radiology Clinical Practice Guideline: Evaluation of Suspected Pulmonary Embolism In Pregnancy. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1200-1208.	5.6	182
8	The role of postâ€™ radiation therapy fdg pet in prediction of necessity for postâ€™ radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1001-1010.	0.8	128
9	Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer?. Annals of Thoracic Surgery, 2002, 73, 394-402.	1.3	124
10	American Thoracic Society Documents: An Official American Thoracic Society/Society of Thoracic Radiology Clinical Practice Guidelineâ€™ Evaluation of Suspected Pulmonary Embolism in Pregnancy. Radiology, 2012, 262, 635-646.	7.3	121
11	Clinical Significance of Postradiotherapy [18F]-Fluorodeoxyglucose Positron Emission Tomography Imaging in Management of Head-and-Neck Cancerâ€™ A Long-Term Outcome Report. International Journal of Radiation Oncology Biology Physics, 2009, 74, 9-14.	0.8	108
12	Update on 18F-Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Imaging of Squamous Head and Neck Cancers. Seminars in Nuclear Medicine, 2005, 35, 214-219.	4.6	91
13	Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: A preliminary report. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1410-1418.	0.8	90
14	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas, 2020, 49, 863-881.	1.1	88
15	Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide. Seminars in Nuclear Medicine, 2002, 32, 92-96.	4.6	80
16	Kinetic Analysis of 3â€™-Deoxy-3â€™-18F-Fluorothymidine (18F-FLT) in Head and Neck Cancer Patients Before and Early After Initiation of Chemoradiation Therapy. Journal of Nuclear Medicine, 2009, 50, 1028-1035.	5.0	77
17	NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷ Lu-DOTATATE Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2020, 61, 222-227.	5.0	77
18	Radiopeptide Imaging and Therapy in the United States. Journal of Nuclear Medicine, 2011, 52, 56S-63S.	5.0	73

#	ARTICLE	IF	CITATIONS
19	Phase I Trial of ⁹⁰ Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1524-1531.	5.0	72
20	Pathology and FDG PET Correlation of Residual Lymph Nodes in Head and Neck Cancer After Radiation Treatment. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 264-270.	1.3	63
21	Single Photon Emission Computed Tomography (SPECT) Should be Routinely Performed for the Detection of Parathyroid Abnormalities Utilizing Technetium-99m Sestamibi Parathyroid Scintigraphy. <i>Clinical Nuclear Medicine</i> , 2009, 34, 651-655.	1.3	61
22	Minimally Invasive Parathyroidectomy and Preoperative MIBI Scans: Correlation of Gland Weight and Preoperative PTH. <i>Journal of the American College of Surgeons</i> , 2007, 205, S38-S44.	0.5	53
23	Technical Note: Single time point dose estimate for exponential clearance. <i>Medical Physics</i> , 2018, 45, 2318-2324.	3.0	53
24	The Utility of ^{99m} Tc Depreotide Compared With F-18 Fluorodeoxyglucose Positron Emission Tomography and Surgical Staging in Patients With Suspected Non-small Cell Lung Cancer. <i>Chest</i> , 2004, 125, 494-501.	0.8	41
25	A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy. <i>Radiotherapy and Oncology</i> , 2011, 99, 49-54.	0.6	39
26	Evaluating the clinical effectiveness of ⁹⁰ Y-SMT 487 in patients with neuroendocrine tumors. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1556-60.	5.0	37
27	Automated cassette-based production of high specific activity [²⁰³ Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer. <i>Applied Radiation and Isotopes</i> , 2017, 127, 52-60.	1.5	36
28	⁹⁰ Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1692-1698.	5.0	36
29	Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors. <i>Surgery</i> , 2017, 161, 272-279.	1.9	35
30	Gastroenteropancreatic neuroendocrine tumors in children and young adults. <i>Pediatric Radiology</i> , 2008, 38, 251-259.	2.0	34
31	Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors. <i>Pancreas</i> , 2017, 46, 151-156.	1.1	34
32	The Value of Preoperative Imaging in Small Bowel Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2013, 20, 1912-1917.	1.5	32
33	Efficacy and Safety of Repeated Samarium-153 Lexidronam Treatment in a Patient with Prostate Cancer and Metastatic Bone Pain. <i>Clinical Nuclear Medicine</i> , 2000, 25, 698-700.	1.3	30
34	Posttreatment FDG-PET Uptake in the Supraglottic and Glottic Larynx Correlates With Decreased Quality of Life After Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 386-392.	0.8	30
35	Frontal hypometabolism in elderly breast cancer survivors determined by [¹⁸ F]fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 587-594.	2.7	30
36	Use of Lymphoscintigraphy With SPECT/CT for Sentinel Node Localization in a Case of Vaginal Melanoma. <i>Clinical Nuclear Medicine</i> , 2006, 31, 201-202.	1.3	29

#	ARTICLE	IF	CITATIONS
37	Spatial mapping of functional pelvic bone marrow using FLT PET. Journal of Applied Clinical Medical Physics, 2014, 15, 129-136.	1.9	29
38	Localization of Unknown Primary Site with ⁶⁸ Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor. Journal of Nuclear Medicine, 2017, 58, 1054-1057.	5.0	29
39	Dependency of cardiac rubidium-82 imaging quantitative measures on age, gender, vascular territory, and software in a cardiovascular normal population. Journal of Nuclear Cardiology, 2015, 22, 72-84.	2.1	28
40	Using [18F]Fluorothymidine Imaged With Positron Emission Tomography to Quantify and Reduce Hematologic Toxicity Due to Chemoradiation Therapy for Pelvic Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2016, 96, 228-239.	0.8	28
41	FLT PET Radiomics for Response Prediction to Chemoradiation Therapy in Head and Neck Squamous Cell Cancer. Tomography, 2019, 5, 161-169.	1.8	28
42	³ deoxy- ³ [18F]fluorothymidine PET Quantification of Bone Marrow Response to Radiation Dose. International Journal of Radiation Oncology Biology Physics, 2011, 81, 888-893.	0.8	27
43	Repeatability of Gallium-68 DOTATOC Positron Emission Tomographic Imaging in Neuroendocrine Tumors. Pancreas, 2013, 42, 937-943.	1.1	23
44	Limitations of somatostatin scintigraphy in primary small bowel neuroendocrine tumors. Journal of Surgical Research, 2014, 190, 548-553.	1.6	23
45	Effects of Intravenous Amino Acid Administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTherâ,ç]) Treatment. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 35-41.	1.0	19
46	Investigation of the pharmacokinetics of ³ -deoxy- ³ [18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Nuclear Medicine and Biology, 2010, 37, 433-438.	0.6	19
47	Change of Maximum Standardized Uptake Value Slope in Dynamic Triphasic [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Distinguishes Malignancy From Postradiation Inflammation in Head-and-Neck Squamous Cell Carcinoma: A Prospective Trial. International Journal of Radiation Oncology Biology Physics, 2015, 91, 472-479.	0.8	19
48	Preliminary Investigation of Cerebral Blood Flow and Amyloid Burden in Veterans With and Without Combat-Related Traumatic Brain Injury. Journal of Neuropsychiatry and Clinical Neurosciences, 2016, 28, 89-96.	1.8	18
49	Cerebral blood flow and neuropsychological functioning in elderly vascular disease patients. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 220-225.	1.3	17
50	Potential increased tumor-dose delivery with combined ¹³¹ I-MIBG and ⁹⁰ Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. Journal of Nuclear Medicine, 2006, 47, 660-7.	5.0	17
51	^{99m} Tc-depreotide tumour uptake in patients with non-Hodgkin's lymphoma. Nuclear Medicine Communications, 2004, 25, 839-843.	1.1	16
52	Radionuclide Cisternography in Detecting Cerebrospinal Fluid Leak in Spontaneous Intracranial Hypotension. Clinical Nuclear Medicine, 2009, 34, 410-416.	1.3	16
53	Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature. American Journal of Neuroradiology, 2020, 41, 1550-1557.	2.4	15
54	Assessment of Hepatic Toxicity from Treatment with ⁹⁰ Y-SMT 487 (OctreoTherâ,ç) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 581-588.	1.0	14

#	ARTICLE	IF	CITATIONS
55	Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies. <i>Pediatric Blood and Cancer</i> , 2008, 50, 561-566.	1.5	13
56	Polyazamacrocycle Ligands Facilitate ⁸⁹ Zr Radiochemistry and Yield ⁸⁹ Zr Complexes with Remarkable Stability. <i>Inorganic Chemistry</i> , 2020, 59, 17473-17487.	4.0	13
57	MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use. <i>Journal of Nuclear Medicine</i> , 2005, 46 Suppl 1, 55S-61S.	5.0	13
58	Positron Emission Tomography/Computed Tomography Imaging of Head and Neck Tumors: An Atlas. <i>Seminars in Nuclear Medicine</i> , 2005, 35, 220-252.	4.6	12
59	Feasibility and advantage of adding ¹³¹ I-MIBG to ⁹⁰ Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. <i>EJNMMI Research</i> , 2014, 4, 38.	2.5	12
60	A Framework for Patient-Centered Pathways of Care for Radiopharmaceutical Therapy: An ASTRO Consensus Document. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 913-922.	0.8	12
61	PET-CT scans in recurrent or persistent differentiated thyroid cancer: Is there added utility beyond conventional imaging?. <i>Surgery</i> , 2010, 148, 1082-1090.	1.9	11
62	Addition of ¹³¹ I-MIBG to PRRT (⁹⁰ Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1274-1277.	5.0	11
63	Tc-99m Red Blood Cell Imaging in a Patient With Blue Rubber Bleb Nevus Syndrome. <i>Clinical Nuclear Medicine</i> , 2008, 33, 374-376.	1.3	10
64	A Comparison Between Diagnostic I-123 and Posttherapy I-131 Scans in the Detection of Remnant and Locoregional Thyroid Disease. <i>Clinical Nuclear Medicine</i> , 2009, 34, 745-748.	1.3	10
65	Nuclear Imaging of Neuroendocrine Tumors. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 209-221.	1.5	10
66	Radiopharmaceuticals for Neuroendocrine Tumors. <i>Seminars in Radiation Oncology</i> , 2021, 31, 60-70.	2.2	10
67	Potential for Increasing Uptake of Radiolabeled ⁶⁸ Ga-DOTATOC and ¹²³ I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 632-641.	1.0	9
68	The Impact of Radiopharmaceutical Therapy on Renal Function. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 467-474.	4.6	9
69	Current Management of Radioiodine Sialadenitis. <i>Current Otorhinolaryngology Reports</i> , 2014, 2, 70-84.	0.5	8
70	Incidental Meningioma Detected on ¹⁸ F-Fluoride With PET/CT During Initial Staging for Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2015, 40, 596-597.	1.3	8
71	Association of gallbladder hyperkinesia with acalculous chronic cholecystitis: A case-control study. <i>Surgery</i> , 2020, 168, 800-808.	1.9	8
72	Giant vertebral hemangioma masquerading as aggressive tumor: Tc-99m tagged RBC scan can help to solve the diagnostic conundrum!. <i>Radiology Case Reports</i> , 2019, 14, 1360-1363.	0.6	7

#	ARTICLE	IF	CITATIONS
73	Safety and accuracy of Ga-DOTATOC PET/CT in children and young adults with solid tumors. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 228-235.	1.0	7
74	Early Phase PIBâ€PET as a Surrogate for Global and Regional Cerebral Blood Flow Measures. Journal of Neuroimaging, 2019, 29, 85-96.	2.0	6
75	Prospective Analysis of the Impact of 68Ga-DOTATOC Positron Emission Tomographyâ€Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors. Pancreas, 2020, 49, 1033-1036.	1.1	6
76	Posterior Reversible Encephalopathy Syndrome on 18F-FDG PET/CT in a Pediatric Patient With Burkittâ€™s Lymphoma. Clinical Nuclear Medicine, 2018, 43, 195-198.	1.3	5
77	Clinical Utility of Pretreatment and 3-Month 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Standardized Uptake Value in Predicting and Assessing Recurrence in T3-T4 Laryngeal Carcinoma Treated With Definitive Radiation. Annals of Otolaryngology and Rhinology, 2019, 128, 595-600.	1.1	4
78	Comparison of T ₁ -Weighted MRI, Glucose Metabolism, and Amyloid Burden Across the Cognitive Spectrum: A Pilot Study. Journal of Neuropsychiatry and Clinical Neurosciences, 2020, 32, 352-361.	1.8	4
79	Multiparametric magnetic resonance imaging and positron emission tomography findings in neurodegenerative diseases: Current status and future directions. Neuroradiology Journal, 2021, 34, 263-288.	1.2	4
80	Comparison of cardiac to hepatic uptake of 99mTc-tetrofosmin with and without adenosine infusion to predict the presence of haemodynamically significant coronary artery disease. Nuclear Medicine Communications, 2005, 26, 513-518.	1.1	3
81	Stability of 3-Deoxy- ¹⁸ F-Fluorothymidine Standardized Uptake Values in Head and Neck Cancer Over Time. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 361-363.	1.0	3
82	PET Imaging During Radiotherapy of Head and Neck Cancer. Journal of Nuclear Medicine, 2013, 54, 497-498.	5.0	3
83	Regional Myocardial Remodeling Characteristics Correlates With Cardiac Events in Sarcoidosis. Journal of Magnetic Resonance Imaging, 2020, 52, 499-509.	3.4	3
84	FDG Positron Emission Tomographic Imaging of Pseudo-pseudo Tumor. Clinical Nuclear Medicine, 2002, 27, 445-446.	1.3	3
85	New Tracers PET in Head and Neck Squamous Cell Carcinoma. PET Clinics, 2012, 7, 431-441.	3.0	2
86	FDG PET Imaging of Head and Neck Cancers. Methods in Molecular Biology, 2011, 727, 21-31.	0.9	2
87	Potential False-Positive Meckelâ€™s Scan Caused by Umbilical Ornamentation. Clinical Nuclear Medicine, 2020, 45, 735-737.	1.3	2
88	Reply: Peptide Receptor Radionuclide Therapy in the United States. Journal of Nuclear Medicine, 2012, 53, 840-840.	5.0	0
89	Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. , 2017, , 411-427.		0
90	Functional Imaging in the Assessment of Normal Tissue Injury Following Radiotherapy. , 2012, , 195-215.		0